This could involve the development of small molecule inhibitors, monoclonal antibodies, or other modalities designed to interfere with the proteolytic function of PSMA4, potentially slowing tumor progression or enhancing the efficacy of existing treatments. This evidence concerns the gene PSMA4 and neoplasm.